Description
Melan – A/MART – 1 Peptide
| Catalog number: | B2012804 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 500 ug |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Lyophilized Powder |
| Applications: | molecular tool for various biochemical applications |
| Storage: | 2-8C |
| Keywords: | Melan A/MART 1 (24 34) |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Tarbe M, Miles JJ, Edwards ESJ, Miles KM, Sewell AK, Baker BM, Quideau S. Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-1(26(27L)-35) ChemMedChem. 2020 May 6;15(9):799-807.
- Tiwari R, Geliebter J, Lucchese A, Mittelman A, Kanduc D. Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity Peptides. 2004 Nov;25(11):1865-71.
- Romero P, Speiser DE, Rufer N. Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans Eur J Immunol. 2014 Sep;44(9):2567-70.
- Bettinotti MP, Kim CJ, Lee KH, Roden M, Cormier JN, Panelli M, Parker KK, Marincola FM. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy J Immunol. 1998 Jul 15;161(2):877-89.
- Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, Sidney J, Sette A, Storkus WJ. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):400-5.
- Hofbauer GF, Kamarashev J, Geertsen R, Bni R, Dummer R. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution Melanoma Res. 1998 Aug;8(4):337-43.
- Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers J Immunol. 2006 Nov 15;177(10):6769-79.
- Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood. 2009 Aug 20;114(8):1537-44.
- Balasse E, Gatouillat G, Patigny D, Andry MC, Madoulet C. In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide Vaccine. 2009 Oct 19;27(44):6107-9.
